Novel transcript, antisense to GNG2

Novel transcript, antisense to GNG2 (LOC102723604; Ensembl: ENSG00000258928), is a putative long non-coding RNA (lncRNA) gene transcribed in the antisense direction relative to the GNG2 (G protein subunit gamma 2) gene. There is currently no characterized protein product, established biological function, molecular mechanism, or association with disease or drug interaction reported in public gene annotation resources. The gene is annotated as “uncharacterized,” and its cellular role and relevance, if any, remain unknown in the scientific literature[3][2]. This entry is distinct from the nearby or overlapping protein-coding gene GNG2 (G protein subunit gamma 2), which is a subunit of heterotrimeric G proteins involved in cell signaling and has been studied in various cellular and disease contexts, such as acting as a tumor suppressor in breast cancer[1][5]. LOC102723604 (ENSG00000258928) is an lncRNA, not a receptor, enzyme, transporter, or other classical drug target molecule[3][2]. There is no evidence or claim in the current data and gene annotation databases that LOC102723604 is a therapeutic or biological target. This gene does not correspond to a well-studied or recognized therapeutic target. There are no known drugs, mechanisms of action, disease roles, or biomarkers associated with it. It is best described as an uncharacterized long non-coding RNA gene with no established molecular function or clinical relevance at this time[3][2].

Other names

LOC102723604ENSG00000258928HSALNG0101258Lnc-NID2-6[3]